The Min-ePump™, a miniaturized, implantable drug delivery device, will allow for on demand delivery of drugs and therapeutics.
FAYETTEVILLE, Ark. – August 24, 2017 – SFC Fluidics® is very pleased to announce it has received $1.5 million Phase II Small Business Innovation Research funding from the National Institutes of Health for the development of an implantable, wirelessly controlled, rapid dosing drug delivery system for small animal research. The Min-ePump™ implantable drug delivery pump will allow real-time, remote controlled delivery of drugs and therapeutics to animal models for addiction and behavior research studies. This system will allow for improved testing methods, as currently animals are required to be tethered to a pump and tested in isolation.
Key research areas that can benefit from untethered animal behavior models include substance abuse, mood disorders, schizophrenia, choice behavior, sleep behavior, stimulus response, relapse, anxiety, avoidance, PTSD, chronic stress, aggressive behavior, cognition, depression, Alzheimer’s disease, Parkinson’s disease, aging disorders and management of chronic pain in humans. Additionally, the Min ePump™ will provide tremendous advantages for the development of a simple patch pump and artificial pancreas for people with diabetes. This technology will allow for miniaturization that will offer people with diabetes a new level of convenience and discretion to manage their diabetes.
SFC Fluidics, Inc. has a mission to advance healthcare and improve quality of life through our enabling microfluidic technologies. The company’s vision is to become a recognized global leader in the drug delivery and health monitoring markets where our unique product lines improve lifestyle and affordability. SFC Fluidics® is a VIC Technology Venture Development™ portfolio company.
Research reported in this release was supported by The National Institute of Drug Abuse of the National Institutes of Health under grant number [2R44DA041173-02]. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
ASHLEY SHEMAIN, VP OF MARKETING & BUSINESS DEVELOPMENT
SFC Fluidics, Inc.
(678) 601 5370